Niclofolan

Niclofolan

SCHEMBL1498232

O=[N+]([O-])c1cc(Cl)cc(-c2cc(Cl)cc([N+](=O)[O-])c2O)c1O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 8/20 0.57
TTR P02766 2/20 0.53
MAPT P10636 4/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
RECQL P46063 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niclofolan SCHEMBL29385615 1.00 GPR35 (0.57) GPR35TTRMAPTMEN1KMT2A
SCHEMBL6010796 0.89 GPR35 (0.63) GPR35TTRMAPTMEN1KMT2A
SCHEMBL4172077 0.83 TTR (0.67) GPR35TTRMAPTMEN1KMT2A
SCHEMBL310420 0.83 GPR35 (0.69) GPR35TTRMAPTMEN1KMT2A
SCHEMBL11306670 0.82 TTR (0.57) GPR35TTRMAPTMEN1KMT2A
SCHEMBL5110264 0.81 AKR1C4 (0.56) GPR35TTRMAPTMEN1KMT2A
SCHEMBL2404933 0.81 TTR (0.48) GPR35TTRMAPTMEN1KMT2A
SCHEMBL28045327 0.80 GPR35 (0.53) GPR35TTRMAPTMEN1KMT2A
SCHEMBL18304977 0.80 TTR (0.54) GPR35TTRMAPTMEN1KMT2A
SCHEMBL1248770 0.80 GPR35 (0.65) GPR35TTRMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632656-B1 IMAGE DATA PROCESSING METHOD FOR PRINTING TECHNOLOGY AND PRINTING SYSTEM ZHUHAI SAILNER 3D TECH CO LTD (CN) 2025-08-06 EP claimed
EP-4586826-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL In the Bowl Animal Health, Inc. (US) 2025-07-23 EP claimed
WO-2024059837-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL IN THE BOWL ANIMAL HEALTH, INC. (US) 2024-03-21 WO claimed
CN-115957192-A Preparation method of nitrochlorophenol tablet and nitrochlorophenol compound tablet 成都乾坤动物药业股份有限公司 2023-04-14 CN claimed
US-20210128690-A1 METHODS OF ADMINISTERING HEPCIDIN LA JOLLA PHARMACEUTICAL COMPANY 2021-05-06 US claimed
EP-3558343-A1 METHODS OF ADMINISTERING HEPCIDIN La Jolla Pharmaceutical Company (US) 2019-10-30 EP claimed
CN-110312521-A Method of administering hepcidin 拉卓拉药物公司 2019-10-08 CN claimed
EP-3078664-B1 ANTIPARASITIC DIHYDROAZOLE COMPOSITIONS MERIAL INC (US) 2019-02-20 EP claimed
WO-2018118979-A1 METHODS OF ADMINISTERING HEPCIDIN LA JOLLA PHARMACEUTICAL COMPANY (US) 2018-06-28 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2004006906-A2 METHODS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO claimed
EP-0710105-A4 SYNERGISTIC ANTHELMINTIC COMPOSITIONS UNIV AUSTRALIAN (AU) 1998-06-10 EP claimed
EP-0710105-A1 SYNERGISTIC ANTHELMINTIC COMPOSITIONS THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1996-05-08 EP claimed
WO-1994028887-A1 SYNERGISTIC ANTHELMINTIC COMPOSITIONS THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1994-12-22 WO claimed
US-4957494-A Multi-layer delivery system ALZA CORPORATION (US) 1990-09-18 US claimed
US-4874388-A Multi-layer delivery system ALZA CORPORATION (US) 1989-10-17 US claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4096262-A VETERINARY MEDICINE BAYER AKTIENGESELLSCHAFT (DT) 1978-06-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128690-A1 METHODS OF ADMINISTERING HEPCIDIN HAMP, FTH1, HDGF GPR35 3790/4885TTR 432/4885MAPT 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.